Page 5,043«..1020..5,0425,0435,0445,045..5,0505,060..»

Cure for Alzheimer's and Parkinson's disease a step closer

Posted: Published on July 19th, 2013

Published: 7:35PM Thursday July 18, 2013 Source: ONE News New Zealand scientists have made a breakthrough in stem cell research, taking a cure for Alzheimer's and Parkinson's disease one step closer. While the study has found what is preventing some stem cells from becoming neurons, scientists at Auckland's University Centre for Brain Research have pinned down the culprit at a cellular level. They found that stem cells have to move around the brain to find their place in order to produce a coat of slippery molecules to make it easy to move. Once in place, they absorb the slippery layer and become neurons, connecting with other neurons to form circuits. "It's a little bit like putting soap on yourself before you go down a hydro slide, it makes the journey a lot less friction filled," Dr Maurice Curtis from the Centre for Brain Research said. "The cells do a similar thing. But when they get to the right location they need to be able to remove that slippery coating in order to stop and intergrate to form networks." In brains with diseases like Alzheimer's and Parkinson's, the slippery coat stays on the outside of the cell which makes it hard … Continue reading →

Posted in Stem Cell Research | Comments Off on Cure for Alzheimer's and Parkinson's disease a step closer

Laughter the best medicine for incurable disorder

Posted: Published on July 19th, 2013

Topics: editors picks, laughter, maryborough, medicine, rieters disease DANIEL Gassman was diagnosed with the rare, incurable genetic disorder Rieters syndrome but he believes the best medicine for him is laughter. The gene is triggered by a viral infection and Daniel said he believed the disease kicked in after enduring a four-month stint with the flu in 2000. "I would bump myself and the pain would last two or more weeks and then my vision started to blur," Daniel said. "For two-and-a-half years I went from doctor to doctor trying to find out what was going on. "My current GP is absolutely brilliant - he did a few tests and sent me to a specialist. "I visited Professor Nash in Maroochydore - he asked me a couple of questions, got me to walk and said I know what you've got, I just have to do a blood test to prove it." The 37-year-old said he was diagnosed with Reiters disease - a roaming rheumatoid arthritis. "I can wake up one morning and my knees aren't working and the next morning my knees are fine and then my hands aren't working," he said. "There could be days were I was scared to … Continue reading →

Comments Off on Laughter the best medicine for incurable disorder

Pilita Corrales reveals secret to looking young

Posted: Published on July 19th, 2013

MANILA - Veteran singer Pilita Corrales believes she does not need stem cell therapy to continue looking young. In an interview with ABS-CBN News on Wednesday, Corrales credited her looks to a positive attitude and a healthy diet. I think its just the attitude of the person living a good life. Really, the most important thing is healthy eating. I have a water diet but you take it with sea salt. I take 10 glasses of water a day with sea salt on the tongue, she said. Corales also believes that one should also avoid vices as these will eventually take a toll on an individual. The singer stressed that she has no plans on undergoing stem cell therapy, saying in jest that she can't afford it anyway even if she wanted to. Me? Ill pay P800,000 or P1 million? I cant afford it. Maybe if you lend me the money, I will, she said, laughing. Some notable personalities who admitted to undergoing stem cell therapy include former presidents Joseph Estrada and Gloria Macapagal Arroyo, and former Senate President Juan Ponce Enrile. Last June, Dangerous Drugs Board chairman Antonio "Bebot" Villar complained of getting zero health benefits from a stem … Continue reading →

Comments Off on Pilita Corrales reveals secret to looking young

Stem Cell Therapy Market in Asia-Pacific to 2018

Posted: Published on July 19th, 2013

DUBLIN, July 18, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/qc7zk2/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity Stem Cell Research in Asia-Pacific a Growth Engine for Region's Scientific Ambitions The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research. Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown. The growth in the stem cell therapy market will not only … Continue reading →

Comments Off on Stem Cell Therapy Market in Asia-Pacific to 2018

Mesoblast Receives $4.3 Million from Australian Government for Adult Stem Cell Pipeline Development

Posted: Published on July 18th, 2013

NEW YORK and MELBOURNE, Australia, July 18, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited today announced that it has received approximately $4.3 million under the Australian Government's Innovation Australia Research and Development (R &D) Tax Incentive Program for R &D activities conducted in Australia during the 2012 financial year. The funds will be used to advance development of Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) technology platform and product pipeline. Based on the Company's ongoing clinical and research activities in Australia across its product portfolio, Mesoblast anticipates that it will make additional submissions in FY2013 and be eligible to receive further reimbursements. About Mesoblast Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is a world leader in the development of biologic products for the broad field of regenerative medicine. The Company's technologies include its proprietary adult Mesenchymal Precursor Cell (MPC) technology platform for bone marrow and adipose tissue derived products, Dental Pulp Stem Cells (DPSCs) and expanded Hematopoietic Stem Cells (HSCs). Mesoblast's allogeneic or 'off-the-shelf' regenerative medicine products focus on repair of damaged issues and modulation of inflammatory responses in conditions with significant unmet medical needs. The lead product candidates use its MPC platform in three major and distinct areas - systemic inflammatory conditions, cardiovascular diseases … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Mesoblast Receives $4.3 Million from Australian Government for Adult Stem Cell Pipeline Development

New research suggests that gingival stem cells can be used in tissue regeneration

Posted: Published on July 18th, 2013

Public release date: 18-Jul-2013 [ | E-mail | Share ] Contact: Ingrid L. Thomas ithomas@iadr.org 703-299-8084 International & American Associations for Dental Research Alexandria, Va., USA Today, the International and American Associations for Dental Research (IADR/AADR) published a paper titled "Gingivae Contain Neural-crest- and Mesoderm-derived Mesenchymal Stem Cells." The paper, written by lead author Songtao Shi, Center for Craniofacial Molecular Biology, Ostrow School of Dentistry, University of Southern California, Los Angeles, USA, is published in the OnlineFirst portion of the IADR/AADR Journal of Dental Research. Gingivae represent a unique soft tissue that serves as a biological barrier to cover the oral cavity side of the maxilla and mandible. Recently, the gingivae were identified as containing mesenchymal stem cells (GMSCs). However, it is unknown whether the GMSCs are derived from cranial neural crest cells (CNCC) or the mesoderm. In this study, Shi and his team of researchers demonstrated that around 90 percent of GMSCs are derived from CNCC and 10 percent from the mesoderm. In comparison with mesoderm MSCs (M-GMSCs), CNCC-derived GMSCs (N-GMSCs) show an elevated capacity to differentiate into neural cells and chondrocytes as well as to modulate immune cells. When transplanted into mice with dextran sulfate sodium-induced colitis, N-GMSCs … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on New research suggests that gingival stem cells can be used in tissue regeneration

Dental research: Gingival stem cells can be used in tissue regeneration

Posted: Published on July 18th, 2013

July 18, 2013 Gingivae represent a unique soft tissue that serves as a biological barrier to cover the oral cavity side of the maxilla and mandible. Recently, the gingivae were identified as containing mesenchymal stem cells (GMSCs). However, it is unknown whether the GMSCs are derived from cranial neural crest cells (CNCC) or the mesoderm. Today, the International and American Associations for Dental Research (IADR/AADR) published a paper titled "Gingivae Contain Neural-crest- and Mesoderm-derived Mesenchymal Stem Cells." The paper, written by lead author Songtao Shi, Center for Craniofacial Molecular Biology, Ostrow School of Dentistry, University of Southern California, Los Angeles, USA, is published in the OnlineFirst portion of the IADR/AADR Journal of Dental Research. In this study, Shi and his team of researchers demonstrated that around 90 percent of GMSCs are derived from CNCC and 10 percent from the mesoderm. In comparison with mesoderm MSCs (M-GMSCs), CNCC-derived GMSCs (N-GMSCs) show an elevated capacity to differentiate into neural cells and chondrocytes as well as to modulate immune cells. When transplanted into mice with dextran sulfate sodium-induced colitis, N-GMSCs showed superior effects in ameliorating inflammatory-related disease phenotype in comparison with the M-GMSC treatment group. Further research is required to understand the interaction … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Dental research: Gingival stem cells can be used in tissue regeneration

Celgene Will Discontinue Phase III ORIGIN® Trial in Previously Untreated Elderly Patients with B-Cell Chronic …

Posted: Published on July 18th, 2013

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that after consultation with the U.S. Food and Drug Administration (FDA) Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries. An imbalance was observed in the number of deaths in patients treated with lenalidomide versus patients treated with chlorambucil. The FDA placed the ORIGIN study on clinical hold on July 12, 2013, with the discontinuation of lenalidomide treatment. All clinical investigators in ongoing chronic lymphocytic leukemia studies using lenalidomide will be officially advised of this action and instructed to inform their patients accordingly. REVLIMID is not approved as a treatment for patients with chronic lymphocytic leukemia. The ORIGIN study was designed to evaluate the efficacy and safety of lenalidomide versus chlorambucil as single agent in elderly patients 65 years of age with B-cell chronic lymphocytic leukemia and with comorbidities that precluded treatment with more aggressive standard chemo-immunotherapies, including fludarabine and bendamustine containing regimens. The majority of patients presented with multiple comorbidities, such as diabetes, congestive heart failure, renal impairment and elevated bilirubin count. Based on an imbalance in deaths, specifically 34 deaths out of 210 patients … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Celgene Will Discontinue Phase III ORIGIN® Trial in Previously Untreated Elderly Patients with B-Cell Chronic …

Stem cells reprogrammed using chemicals alone

Posted: Published on July 18th, 2013

Turning human cells into stem cells without changing their genes could lead to therapies that do not carry a risk of generating mutations. Andrew Brookes/Corbis Scientists have demonstrated a new way to reprogram adult tissue to become cells as versatile as embryonic stem cells without the addition of extra genes that could increase the risk of dangerous mutations or cancer. Researchers have been striving to achieve this since 2006, when the creation of so-called induced pluripotent (iPS) cells was first reported. Previously, they had managed to reduce the number of genes needed using small-molecule chemical compounds, but those attempts always required at least one gene, Oct42, 3. Now, writing in Science, researchers report success in creating iPS cells using chemical compounds only what they call CiPS cells1. Hongkui Deng, a stem-cell biologist at Peking University in Beijing, and his team screened 10,000 small molecules to find chemical substitutes for the gene. Whereas other groups looked for compounds that would directly stand in for Oct4, Deng's team took an indirect approach: searching for small-molecule compounds that could reprogram the cells in the presence of all the usual genes except Oct4. Then came the most difficult part. When the group teamed the … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Stem cells reprogrammed using chemicals alone

Don’t market stem-cell products ahead of proof

Posted: Published on July 18th, 2013

Translational medicine is said to reflect a need to harness the huge wealth of scientific knowledge in biomedicine. In fact, it is a direct consequence of the globalized outsourcing of research and development by the pharmaceutical industry, resting on the creation of commercial enterprises within academia. A commercial drive in academia can, however, significantly alter scientific concepts in biology and medicine. Mesenchymal stem cells (MSCs) provide a prime example of this. Decades of research on these cells, found in the bone marrow, show that they go on to form skeletal tissues such as bone, fat and cartilage, which they can also help to regrow and repair in the clinic. Yet companies have already emerged that market MSCs for a much broader range of applications. Against mainstream scientific evidence, these firms argue that the cells are veritable injectable drug stores. This commercial creep has reached the pages of authoritative scientific journals, with articles suggesting that intravenously infused MSCs can be used as a single agent to mute or cure a long list of unrelated diseases in multiple organs, regardless of their cause and nature. Notably, these include terminal neurodegenerative diseases, strokes and heart attacks. These are extraordinary claims that would require … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Don’t market stem-cell products ahead of proof

Page 5,043«..1020..5,0425,0435,0445,045..5,0505,060..»